DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Fruehauf J, Lutzky J, McDermott D et al
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Clin Cancer Res 2011;
17: 7462-7469
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.